San Francisco, CA – According to filings with the U.S. Securities and Exchange Commission, Telo Therapeutics has raised $4.71 Million in new funding. Sources indicate as part of senior management President, Robert Bell played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Telo Therapeutics

Telo Therapeutics, Inc. is developing a novel, personalized medicine therapeutic to selectively inhibit cancer cell immortality. All cancer cells undergo a process called immortalization, and the majority of cancers achieve this by turning on an enzyme called telomerase. Telomerase is a validated clinical target, yet existing inhibitors are toxic to the bodys normal cells and have so far failed to make it to market. We are developing a novel therapeutic that will reverse immortality specifically in cancer cells and leave healthy cells intact.

To learn more about Telo Therapeutics, visit http://telotherapeutics.com/

Contact:
Robert Bell, President
831-234-8510
robert.bell@telotherapeutics.com
https://www.linkedin.com/in/rob-bell-b722b213/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved